- Home
- COCH vs STTK Comparison
COCH vs STTK Comparison
Compare COCH & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COCH
- STTK
- Stock Information
- Founded
- COCH 1995
- STTK 2016
- Country
- COCH United States
- STTK United States
- Employees
- COCH N/A
- STTK N/A
- Industry
- COCH Blank Checks
- STTK Biotechnology: Pharmaceutical Preparations
- Sector
- COCH Finance
- STTK Health Care
- Exchange
- COCH Nasdaq
- STTK Nasdaq
- Market Cap
- COCH 31.6M
- STTK 37.6M
- IPO Year
- COCH N/A
- STTK 2020
- Fundamental
- Price
- COCH $1.55
- STTK $0.82
- Analyst Decision
- COCH Strong Buy
- STTK Hold
- Analyst Count
- COCH 2
- STTK 4
- Target Price
- COCH $9.25
- STTK $3.00
- AVG Volume (30 Days)
- COCH 21.8K
- STTK 396.2K
- Earning Date
- COCH 08-11-2025
- STTK 07-31-2025
- Dividend Yield
- COCH N/A
- STTK N/A
- EPS Growth
- COCH N/A
- STTK N/A
- EPS
- COCH N/A
- STTK N/A
- Revenue
- COCH $212,000.00
- STTK $4,606,000.00
- Revenue This Year
- COCH $8.04
- STTK N/A
- Revenue Next Year
- COCH $15.39
- STTK N/A
- P/E Ratio
- COCH N/A
- STTK N/A
- Revenue Growth
- COCH N/A
- STTK 69.65
- 52 Week Low
- COCH $1.21
- STTK $0.69
- 52 Week High
- COCH $3.99
- STTK $4.99
- Technical
- Relative Strength Index (RSI)
- COCH 43.84
- STTK 37.21
- Support Level
- COCH $1.36
- STTK $0.77
- Resistance Level
- COCH $1.53
- STTK $1.14
- Average True Range (ATR)
- COCH 0.08
- STTK 0.09
- MACD
- COCH 0.00
- STTK -0.03
- Stochastic Oscillator
- COCH 27.78
- STTK 9.88
About COCH Envoy Medical Inc.
Envoy Medical Inc is a hearing health company focused on providing medical technologies. It is dedicated to pushing hearing technology beyond the status quo to provide patients with improved access, usability, independence and quality of life. The Company has one reportable segment: hearing. The hearing segment derives revenue from the sale of the Esteem FI-AMEI implants and replacement components to Esteem FI-AMEI implants.
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.